Table 2 Comparison of clinical characteristics in IBD patients with and without NAFLD.
Variables | NAFLD (n = 245) | non-NAFLD (n = 264) | P value |
|---|---|---|---|
CD (%) | 88 (35.9) | 97 (36.7) | 0.847 |
Duration of IBD, median (IQR), yr | 3.0 (1.0–9.0) | 3.0 (1.0–8.0) | 0.301 |
Prior surgery (%) | 26 (10.6) | 40 (15.2) | 0.128 |
Disease activity | |||
CDAI for CD, mean (SD) | 170.7 (102.8) | 166.4 (90.4) | 0.762 |
Mayo score for UC, mean (SD) | 7.0 (3.0) | 6.6 (3.0) | 0.153 |
EIM (%) | 36 (14.7) | 35 (13.3) | 0.640 |
Extensive disease (%) | 141 (57.6) | 135 (51.1) | 0.147 |
Localization UC (%) | |||
E1 | 35 (22.3) | 54 (32.3) | 0.038 |
E2 | 45 (28.7) | 53 (31.7) | |
E3 | 77 (49.0) | 60 (35.9) | |
Localization CD (%) | |||
L1 | 44 (50.0) | 43 (44.3) | 0.270 |
L2 | 8 (9.1) | 18 (18.6) | |
L3 | 28 (31.8) | 29 (29.9) | |
L4 + L1 | 3 (3.4) | 4 (4.1) | |
L4 + L2 | 0 | 1 (1.0) | |
L4 + L3 | 5 (5.7) | 2 (2.1) | |
CD behavior (%) | |||
B1 | 45 (51.7) | 41 (42.7) | 0.361 |
B2 | 34 (39.1) | 41 (42.7) | |
B3 | 8 (9.2) | 14 (14.6) | |
IBD relapse (%) | 138 (56.3) | 151 (57.2) | 0.843 |
Medications (%) | |||
5-ASA | 183 (74.7) | 197 (74.6) | 0.985 |
Glucocorticoids | 89 (36.3) | 87 (33.0) | 0.424 |
Immunosuppressants | 30 (12.2) | 40 (15.2) | 0.341 |
Biologic agents | 35 (14.3) | 26 (9.8) | 0.124 |
FMT (%) | 11 (4.5) | 5 (1.9) | 0.094 |
